Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes

INTRODUCTION: Nonvalvular atrial fibrillation (NVAF) is associated with a substantial economic burden, particularly in patients with comorbid conditions. This study compared healthcare resource utilization (HRU) and costs of rivaroxaban and warfarin in patients with NVAF, obesity, and diabetes. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Weir, Matthew R., Chen, Yen-Wen, He, Jinghua, Bookhart, Brahim, Campbell, Alicia, Ashton, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586051/
https://www.ncbi.nlm.nih.gov/pubmed/34699020
http://dx.doi.org/10.1007/s13300-021-01161-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586051/
https://www.ncbi.nlm.nih.gov/pubmed/34699020
http://dx.doi.org/10.1007/s13300-021-01161-4

Ejemplares similares